Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

New radical approach to test chemo drugs for potential toxic effects

New radical approach to test chemo drugs for potential toxic effects

NeoPharm presents LE-DT Phase I data at the AACR conference

NeoPharm presents LE-DT Phase I data at the AACR conference

Genentech submits sBLAs to the FDA for Avastin

Genentech submits sBLAs to the FDA for Avastin

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

Combination therapy before prostate removal may prevent recurrence of cancer

Combination therapy before prostate removal may prevent recurrence of cancer

NeoPharma submits a Phase II protocol to the FDA for its liposome entrapped docetaxel study

NeoPharma submits a Phase II protocol to the FDA for its liposome entrapped docetaxel study

Astellas enters into agreement with Medivation to develop MDV3100

Astellas enters into agreement with Medivation to develop MDV3100

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Peregrine Pharmaceuticals reports positive results from Phase II trial of bavituximab

Phyton Biotech purchases NPI’s assets

Phyton Biotech purchases NPI’s assets

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

Medivation commences patient treatment in clinical trial of MDV3100 in advanced prostate cancer

Medivation commences patient treatment in clinical trial of MDV3100 in advanced prostate cancer

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

FDA approves Supplemental New Drug Application for DOXIL

FDA approves Supplemental New Drug Application for DOXIL

Patient enrollment completed in Phase II clinical trial of bavituximab

Patient enrollment completed in Phase II clinical trial of bavituximab

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

Researchers reveal that genes contributing to drug resistance in NSCLC disease could be predicted

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

ADVENTRX Pharmaceuticals announces closing of financing

ADVENTRX Pharmaceuticals announces closing of financing

Array Biopharma reports Q4 and full year 2009 financials

Array Biopharma reports Q4 and full year 2009 financials

Gene that stops or suppress cancer plays a role in cancer stem cells

Gene that stops or suppress cancer plays a role in cancer stem cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.